Capital, M&A & Industry Strategy
Generate Bio drops as data accidentally leaked ahead of European conference
Capital, M&A & Industry Strategy
Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
Electra Therapeutics is hoping to raise up to $341.9 million from an IPO in order to power the clinical development of its inflammatory disorder drug, ipsoprubart.
Capital, M&A & Industry Strategy
Eco-NAMs Webinar Series | QSARs to Predict Aquatic Toxicity – 09/17/2026
The Eco-NAMs Webinar Series aims to present the most informative and up-to-date science on new approach methodologies (NAMs) for ecotoxicity assessments
Capital, M&A & Industry Strategy
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin Group.
RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin Group.
Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
Psychedelic therapies ride wave of public favor into FDA hearing
After a brief storm of political headwinds, mRNA is back with strong momentum
-
Fierce Biotech6 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Endpoints News6 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized6 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Nature Biotechnology6 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Uncategorized4 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized4 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
STAT News – Biotech6 months agoSTAT+: In private meetings, White House works to win pharma companies’ support for drug pricing bill
-
BioPharma Dive – AI / Data6 months agoAstraZeneca lung drug gets ‘surprise’ win in COPD trials
Scan to Read